Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

PASG

+ Watchlist+ Portfolio

Passage Bio, Inc.

Regulated industryDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$4.22
52-Week Range
$3.29 – $20.00
Market Cap
$13.31M
P/E (TTM)
—
EPS (TTM)
-10.35
Dividend Yield
0.00%
Advanced Metrics
Price/Book
258.44
PEG Ratio
—
Return on Equity
-212.27%
Return on Assets
-45.26%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
1.00
Debt/Equity
—
Total Debt
$0.00
Free Cash Flow
$-14.79M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$-6.85M

Market Snapshot

About

Passage Bio is a clinical-stage genetic medicines company focused on developing AAV-delivered gene therapies for central nervous system disorders. The company leverages its platform to target rare neurological diseases with potentially transformative one-time treatments, aiming to address significant unmet medical needs in CNS conditions.